Burnier M - Search Results

1

CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt.

Eap CB, Bochud M, Elston RC, Bovet P, Maillard MP, Nussberger J, Schild L, Shamlaye C, Burnier M. Eap CB, et al. Among authors: burnier m. Hypertension. 2007 May;49(5):1007-14. doi: 10.1161/HYPERTENSIONAHA.106.084236. Epub 2007 Mar 19. Hypertension. 2007. PMID: 17372036

2

Evaluation of arterial compliance-pressure curves. Effect of antihypertensive drugs.

Perret F, Mooser V, Hayoz D, Tardy Y, Meister JJ, Etienne JD, Farine PA, Marazzi A, Burnier M, Nussberger J, et al. Perret F, et al. Among authors: burnier m. Hypertension. 1991 Oct;18(4 Suppl):II77-83. doi: 10.1161/01.hyp.18.4_suppl.ii77. Hypertension. 1991. PMID: 1680813 Clinical Trial.

3

Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition.

Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR. Mooser V, et al. Among authors: burnier m. J Cardiovasc Pharmacol. 1990 Feb;15(2):276-82. doi: 10.1097/00005344-199002000-00015. J Cardiovasc Pharmacol. 1990. PMID: 1689424 Clinical Trial.

4

[The treatment of arterial hypertension: which drug for which patient?].

Wafber B, Niederberger M, Nussberger J, Burnier M, Brunner HR. Wafber B, et al. Among authors: burnier m. Schweiz Rundsch Med Prax. 1992 Jan 14;81(3):32-6. Schweiz Rundsch Med Prax. 1992. PMID: 1732999 Review. French.

5

Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers.

Burnier M, Ganslmayer M, Perret F, Porchet M, Kosoglou T, Gould A, Nussberger J, Waeber B, Brunner HR. Burnier M, et al. Clin Pharmacol Ther. 1991 Aug;50(2):181-91. doi: 10.1038/clpt.1991.123. Clin Pharmacol Ther. 1991. PMID: 1831083 Clinical Trial.

6

Comparative cardiovascular effects of drugs used for hypertension.

Burnier M, Waeber B, Nussberger J, Brunner HR. Burnier M, et al. Drugs. 1990;39 Suppl 1:32-8. doi: 10.2165/00003495-199000391-00006. Drugs. 1990. PMID: 1968375 Review.

7

Use of non-invasive ambulatory blood pressure monitoring to screen for high-risk hypertensive patients.

Christen Y, Ganslmayer M, Waeber B, Burnier M, Nussberger J, Brunner HR. Christen Y, et al. Among authors: burnier m. J Hypertens Suppl. 1990 Dec;8(6):S119-24. J Hypertens Suppl. 1990. PMID: 2081993

8

Determination of plasma catecholamine and vasoactive peptide concentrations: clinical usefulness.

Waeber B, Nussberger J, Grouzmann E, Burnier M, Brunner HR. Waeber B, et al. Among authors: burnier m. Int J Rad Appl Instrum B. 1990;17(7):667-72. doi: 10.1016/0883-2897(90)90082-c. Int J Rad Appl Instrum B. 1990. PMID: 2148169 Review. No abstract available.

9

Role of atrial natriuretic peptides and neuropeptide Y in blood pressure regulation.

Waeber B, Burnier M, Nussberger J, Brunner HR. Waeber B, et al. Among authors: burnier m. Horm Res. 1990;34(3-4):161-5. doi: 10.1159/000181817. Horm Res. 1990. PMID: 2151774 Review.

10

Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations.

Brunner HR, Ménard J, Waeber B, Burnier M, Biollaz J, Nussberger J, Bellet M. Brunner HR, et al. Among authors: burnier m. J Hypertens. 1990 Jan;8(1):3-11; discussion 13-9. doi: 10.1097/00004872-199001000-00002. J Hypertens. 1990. PMID: 2157754 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,168 results

Search Page

Filters